NEW YORK (GenomeWeb) – Following on the successful development of a genetic test for heritable jaundice, researchers from Cincinnati Children's Hospital Medical Center (CCHMC) and specialty pharmaceutical firm P2D have begun work on a next-generation sequencing assay to identify mutations associated with inherited forms of pancreatitis.

Meantime, P2D and CCHMC continue to work on a follow up to the jaundice test that will use next-gen sequencing to screen for genetic mutations in order to diagnose a number of additional liver diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Sponsored by

In these times of economic constraint and increasing research costs, shared resource cores have become a cost-effective and essential platform for researchers who seek to investigate complex translational research questions.